Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ASCO 2018: Optimism As Industry Resets And Looks To What Is Next

Jun 04 2018

• By Jessica Merrill

River view of city ASCO 2018 — Downtown Chicago

Related Content

Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion

Apr 08 2018

Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy

Jun 10 2013

ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC

Apr 24 2018

A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug

Apr 30 2018

Bluebird's BCMA CAR-T Sings At ASCO, But How Will It Fly In Early Multiple Myeloma?

Jun 02 2018

Merck's Keytruda Monotherapy May Get Stuck With Small Role In First-line Lung Cancer

Jun 04 2018

A Plea For Patience: Bristol/Nektar's Opdivo/NKTR-214 Combo Responses Deepen Over Time

Jun 03 2018

Loxo '292 And Cancer Drug Development Today: So Much Promise, So Many Questions

Jun 03 2018

Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice

Jun 05 2017

Related Companies

Pfizer Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

Loxo Oncology at Lilly

AstraZeneca PLC

Bluebird Bio

Bristol Myers Squibb Company

Incyte Corporation

Novartis AG

Nektar Therapeutics

Additional Topics

ImmunoOncology Clinical Trials Research & Development Commercial ASCO

More from ASCO

More from Conferences

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.